Mian Hira S, Wildes Tanya M, Fiala Mark A
Hira S. Mian, McMaster University, Hamilton, Ontario, Canada; and Tanya M. Wildes and Mark A. Fiala, Washington University School of Medicine, St. Louis, MO.
JCO Clin Cancer Inform. 2018;2. doi: 10.1200/CCI.18.00043. Epub 2018 Jul 25.
To develop a frailty index using the Rockwood Accumulation of Deficits approach for the Medicare Health Outcomes Survey (MHOS) and apply it in a subset of older patients with newly diagnosed multiple myeloma.
Data from 2,692,361 patients without cancer, > 66 years of age, in SEER-MHOS linked databases between 1998 and 2009 were analyzed. A frailty index was constructed, resulting in a 25-item scale; cutoff values were created for individuals classified as frail. This frailty index was then applied to 305 patients with newly diagnosed myeloma in the database to predict overall survival.
In the derivation cohort of patients without cancer, the median age was 74 years and the mean frailty index was 0.23 (standard deviation, 0.17). Among patients without cancer, each 10% increase in frailty index (approximately three to four more deficits) was associated with a 40% increased risk for death (adjusted hazard ratio, 1.397; 95% CI, 1.396 to 1.399; < .001). In the cohort of patients with newly diagnosed myeloma, the median age was 76 years an d the mean frailty index was 0.28 (standard deviation, 0.17). Each 10% increase in frailty index was associated with a 16% increased risk for death (adjusted hazard ratio, 1.159; 95% CI, 1.080 to 1.244; < .001). Fifty-three percent of patients with multiple myeloma were considered frail. The estimated median overall survival of patients considered frail was 26.8 months, compared with 43.7 months ( = .015) for those who were not.
The MHOS-based frailty index was prognostic for patients with multiple myeloma in predicting overall survival.
采用罗克伍德累积缺陷法为医疗保险健康结果调查(MHOS)制定衰弱指数,并将其应用于新诊断的多发性骨髓瘤老年患者亚组。
分析了1998年至2009年间SEER-MHOS链接数据库中2692361例年龄大于66岁的无癌症患者的数据。构建了一个衰弱指数,形成了一个包含25个条目的量表;为被归类为衰弱的个体设定了临界值。然后将该衰弱指数应用于数据库中305例新诊断的骨髓瘤患者,以预测总生存期。
在无癌症患者的推导队列中,中位年龄为74岁,平均衰弱指数为0.23(标准差为0.17)。在无癌症患者中,衰弱指数每增加10%(约增加三到四个缺陷),死亡风险增加40%(调整后的风险比为1.397;95%置信区间为1.396至1.399;P<.001)。在新诊断的骨髓瘤患者队列中,中位年龄为76岁,平均衰弱指数为0.28(标准差为0.17)。衰弱指数每增加10%,死亡风险增加16%(调整后的风险比为1.159;95%置信区间为1.080至1.244;P<.001)。53%的多发性骨髓瘤患者被认为是衰弱的。被认为衰弱的患者估计中位总生存期为26.8个月,而未被认为衰弱的患者为43.7个月(P = 0.015)。
基于MHOS的衰弱指数对多发性骨髓瘤患者的总生存期具有预后预测价值。